China SXT Pharmaceuticals (SXTC) Total Liabilities (2018 - 2025)

China SXT Pharmaceuticals' Total Liabilities history runs 8 years deep, the most recent figure standing at $6.1 million for Q3 2025.

• In Q3 2025, Total Liabilities fell 61.66% year-over-year to $6.1 million; the TTM figure through Sep 2025 stood at $6.1 million (down 61.66% YoY), while the FY2025 annual figure was $6.2 million, down 32.33% from the prior year.
• Total Liabilities was $6.1 million for Q3 2025 at China SXT Pharmaceuticals, down from $6.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $18.6 million in Q1 2021 to a low of $6.1 million in Q3 2025.
• Historically, Total Liabilities has averaged $11.4 million across 5 years, with a median of $9.4 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities surged 67.82% in 2024, then tumbled 61.66% in 2025.
• A 5-year view of Total Liabilities shows it stood at $8.9 million in 2021, then declined by 17.87% to $7.3 million in 2022, then soared by 30.44% to $9.5 million in 2023, then soared by 67.82% to $16.0 million in 2024, then sank by 61.66% to $6.1 million in 2025.
• The last three Total Liabilities figures came in at $6.1 million (Q3 2025), $6.2 million (Q1 2025), and $16.0 million (Q3 2024), per Business Quant data.